HOMOLOGOUS RECOMBINATION DEFICIENCY
Clinical trials for HOMOLOGOUS RECOMBINATION DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new HOMOLOGOUS RECOMBINATION DEFICIENCY trials appear
Sign up with your email to follow new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Phase: PHASE1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Lung cancer clue: could a DNA glitch open door to new treatments?
Knowledge-focused OngoingThis study looks at a specific DNA repair issue called homologous recombination deficiency (HRD) in people with a type of lung cancer (EGFR-mutated NSCLC). Researchers want to know how common HRD is and whether it relates to how the cancer behaves. They will also test this in lab…
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Prostate cancer study pulled before it began
Knowledge-focused TerminatedThis study was designed to see if a person's race or ethnicity changes how well a combination of drugs (niraparib, abiraterone acetate, and prednisone) works for a specific type of advanced prostate cancer. It planned to compare Black or Hispanic participants with White or Native…
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC